Position SummaryThe Head, Radiopharmaceutical Diagnostic Development will provide strategic and operational leadership for RayzeBio's diagnostic and companion imaging radiopharmaceutical portfolio, including PET and SPECT imaging agents used for patient selection, dosimetry, and disease monitoring across RayzeBio's radioligand therapy (RLT) programs (e.g., RYZ101, RYZ701, and the broader RYZ-series pipeline). This role owns the diagnostic development strategy end to end - from candidate nomination and CMC development through tech transfer, clinical supply, regulatory submission, and health authority approval - and partners closely with CMC, Quality, Regulatory Affairs, Clinical Development, Manufacturing, Isotope Supply Chain, and Commercial to ensure diagnostic agents are delivered on time, in compliance, and aligned to the needs of each therapeutic program. The role is global in scope: it is accountable for building and executing global development plans across the United States, Canada, the European Union, Australia/New Zealand, and the Asia-Pacific region, and for the ongoing lifecycle management of approved diagnostic products across all markets in which RayzeBio operates.
Job Responsibilities- Define and own the diagnostic and companion imaging development strategy across RayzeBio's portfolio, aligning imaging agent timelines with the therapeutic programs they support.
- Build and execute global development plans for diagnostic radiopharmaceuticals, coordinating regulatory strategy, filings, and market entry across the United States, Canada, the European Union, Australia/New Zealand, and the Asia-Pacific region.
- Own lifecycle management for approved diagnostic products, including post-approval changes, label updates, supplemental filings, manufacturing changes, and continued market compliance across all regions in which the products are marketed.
- Tailor regional regulatory and CMC strategies to align with local health authority requirements (e.g., FDA, Health Canada, EMA, TGA, and APAC regulatory bodies) while maintaining a unified global development plan.
- Lead CMC strategy, process development, and validation for diagnostic radiopharmaceuticals, including radiosynthesis, radiolabeling, and quality control methods for isotopes such as Ga-68, F-18, and Cu-64.
- Direct technology transfer and scale-up of diagnostic manufacturing processes across internal sites and third-party CDMOs/CROs, ensuring robust, reproducible, and inspection-ready operations.
- Serve as the primary strategic point of contact with FDA and other health authorities for diagnostic imaging agent submissions, meetings, and inspections, including IND, NDA, and ANDA filings.
- Author and oversee CMC sections, briefing documents, and regulatory correspondence for diagnostic development programs; lead health authority interactions in partnership with Regulatory Affairs.
- Partner with Clinical Development and Translational Medicine to design imaging strategies that support patient selection, dosimetry, and biomarker objectives for RLT clinical trials.
- Build, mentor, and lead a high-performing team of scientists and CMC/regulatory professionals supporting diagnostic development.
- Ensure diagnostic development activities comply with 21 CFR Parts 211 and 212, USP , NRC requirements, and other applicable radiopharmaceutical regulations.
- Manage external supplier, CDMO, and CRO relationships supporting diagnostic manufacturing, analytical testing, and clinical supply.
- Represent RayzeBio externally with industry and standards bodies (e.g., SNMMI, MITA, USP) to help shape evolving standards for diagnostic radiopharmaceuticals.
- Own budget, resourcing, and risk mitigation planning for the diagnostic development function; report progress and risks to senior leadership.
- Identify opportunities to apply digital tools and AI to improve development speed, data integrity, and decision-making across diagnostic programs.
- Willing to travel approximately 20-30% of the time; occasional evening or weekend work may be required to support inspections or health authority interactions.
Education and Experience- PharmD, PhD, or other advanced scientific degree, with 10+ years of experience in radiopharmaceutical, PET/SPECT diagnostic, or nuclear medicine product development, or an equivalent combination of education and experience.
- Demonstrated success leading CMC and regulatory strategy for diagnostic or companion imaging radiopharmaceuticals through IND-enabling activities and NDA/ANDA approval.
- Hands-on experience with cGMP radiopharmaceutical manufacturing, including cyclotron- or generator-produced isotopes and automated radiosynthesis platforms.
- Track record of leading successful FDA inspections (including pre-approval inspections) and direct health authority interactions.
- Prior people-leadership experience managing cross-functional scientific, regulatory, and/or quality teams.
- Experience building and executing global development and regulatory plans across multiple regions (e.g., US, Canada, EU, Australia/New Zealand, APAC), including lifecycle management of approved products.
- Deep subject-matter expertise in PET/SPECT diagnostic radiopharmaceutical development, manufacturing, and regulatory pathways.
- Strong understanding of companion diagnostic strategy and how imaging agents support patient selection for radioligand therapy programs.
- Proven ability to lead through influence in a matrix organization, building alignment across functions and with senior leadership.
- Strong scientific and regulatory judgment, with the ability to translate complex CMC and clinical data into clear, decision-oriented recommendations.
- Executive-level written and verbal communication skills, including experience representing programs to FDA, investigators, and industry bodies.
- Ability to operate effectively in a highly regulated environment and adhere to RayzeBio's guidelines and standard operating procedures (SOPs).
- Patient-focused, with a genuine commitment to improving outcomes for people with cancer through innovative radiopharmaceuticals.
- Working knowledge of international regulatory frameworks and health authority expectations across North America, Europe, Australia/New Zealand, and the Asia-Pacific region, and experience managing product lifecycle activities on a global scale.
#RayzeBio
Compensation Overview:Remote - United States - US: $221,749 - $268,707
The starting compensation range(s) for this role are listed above for a full-time employee (FTE) basis. Additional incentive cash and stock opportunities (based on eligibility) may be available. The starting pay rate takes into account characteristics of the job, such as required skills, where the job is performed, the employee's work schedule, job-related knowledge, and experience. Final, individual compensation will be decided based on demonstrated experience.
Eligibility for specific benefits listed on our careers site may vary based on the job and location. For more on benefits, please visit https://careers.bms.com/life-at-bms/.
Benefit offerings are subject to the terms and conditions of the applicable plans in effect at the time and may require enrollment. Our benefits include:
- Health Coverage: Medical, pharmacy, dental, and vision care.
- Wellbeing Support: Programs such as BMS Well-Being Account, BMS Living Life Better, and Employee Assistance Programs (EAP).
- Financial Well-being and Protection: 401(k) plan, short- and long-term disability, life insurance, accident insurance, supplemental health insurance, business travel protection, personal liability protection, identity theft benefit, legal support, and survivor support.
Work-life benefits include:Paid Time Off
- US Exempt Employees: flexible time off (unlimited, with manager approval, 11 paid national holidays (not applicable to employees in Phoenix, AZ, Puerto Rico or Rayzebio employees)
- Phoenix, AZ, Puerto Rico and Rayzebio Exempt, Non-Exempt, Hourly Employees: 160 hours annual paid vacation for new hires with manager approval, 11 national holidays, and 3 optional holidays
Based on eligibility*, additional time off for employees may include unlimited paid sick time, up to 2 paid volunteer days per year, summer hours flexibility, leaves of absence for medical, personal, parental, caregiver, bereavement, and military needs and an annual Global Shutdown between Christmas and New Years Day.
All global employees full and part-time who are actively employed at and paid directly by BMS at the end of the calendar year are eligible to take advantage of the Global Shutdown.
*Eligibility Disclosure: The summer hours program is for United States (U.S.) office-based employees due to the unique nature of their work. Summer hours are generally not available for field sales and manufacturing operations and may also be limited for the capability centers. Employees in remote-by-design or lab-based roles may be eligible for summer hours, depending on the nature of their work, and should discuss eligibility with their manager. Employees covered under a collective bargaining agreement should consult that document to determine if they are eligible. Contractors, leased workers and other service providers are not eligible to participate in the program.
RayzeBio and Bristol Myers SquibbRayzeBio was acquired by Bristol Myers Squibb (BMS) in 2024 and is a wholly-owned subsidiary of BMS; however, RayzeBio will continue to operate as a standalone organization.
